seems like they've changed minds on not pushing forward in the US. Happy with this step forward, new CCO probably pushing this as a priority especially with discussions on potential US listing, need to at least have an opportunity for clinical trials and removing the hold is key! Onwards and upwards, combo study next.
Ann: ATL1102 tox study to support clinical program in the US, page-3
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $64.91M | |||
| Open | High | Low | Value | Volume |
| 7.2¢ | 7.4¢ | 7.0¢ | $17.78K | 246.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13800 | 7.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.4¢ | 63495 | 1 |
View Market Depth
| Last trade - 15.22pm 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.4¢ |
Change
0.000 ( 2.78 %) |
||||
| Open | High | Low | Volume | ||
| 7.0¢ | 7.4¢ | 7.0¢ | 44500 | ||
| Last updated 14.24pm 27/05/2024 ? | |||||
| PER (ASX) Chart |